

References

1. Dziak HV, Khaniukov AA. *Ukrayinskyimedychnyichasopys – Ukrainian Medical Journal* 2009;4(72):17–23 (in Ukrainian).
2. Zharinov O. *Liky Ukrainy– Ukraine Medications* 2004;9:93–97 (in Ukrainian).
3. Katerynychuk I, Katerynychuk V. Kyiv,2005.169 p (in Ukrainian).
4. Oshhepkova EV. *Atmosfera.Kardiologija — Atmosphere.Cardiology* 2005;3:39–42 (in Russ).
5. Radchenko HD. *Naukovyisvit*,2008.43p (in Ukrainian).
6. Rekomendacii Ukrainskoi asociacii kardiologiv z profilaktyky ta likuvannja arterialnoi gipertenzii: Posibnyk do Nacionalnoi program profilaktyky I likuvannja arterialnoi gipertenzii (Guidelines of Ukrainian Association of cardiologists for prevention and treatment of hypertension: Guide to the National program for prevention and treatment of hypertension). Kyiv *Biznespoligraf*, 2008.79 p.
7. 2003 European Society of Hypertention – European Society of Cardiology guidelines for management of arterial hypertension. *J Hypertention* 2003;21:1011–53.
8. 2007 European Society of Hypertension – European Society of Cardiology guidelines for management of arterial hypertension. *J Hypertension*2007;25:1105–87.
9. Abraham WT, Tsvetkova T, Lowes BD. Carvedilol improves renal hemodynamics in patients with chronic heart failure. *J Card Fail*1998;98:378–9.
10. Adler AI, Stratton I.M, Neil H, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR of the UK Prospective Study group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.*BMJ*2000;321:412–19.
11. Agrawal B, Wolf K, Berger A, Luft FC. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. *J Hum Hypertens* 1996;10:551–5.
12. Andrus MR, Holloway KP, Clark DB. Use of beta-blockers in patients with COPD. *Ann Pharmacother* 2004;38:142–5.
13. Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, Tonkin A, Perkovic V. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. *J Am Coll Cardiol* 2011;58:1152–61.
14. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial. *JAMA* 2004;292:2227–36.
15. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta blockers: a critical review of the evidence. *J Am CollCardiol* 2007;50:563–72.

16. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment. *Arch Intern Med* 2006;166:2191–201.
17. Beta-blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *JAMA* 1982;247:1707–14.
18. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. *BMJ* 1992;304:339–342.
19. Bradley HA, Wysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. *J Hypertens* 2006;24:2131–41.
20. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? *Lancet* 2004 Nov 6-12;364(9446):1684–9
21. Charlotte H, Manisty & Alun D. Hughes. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. DOI: 10.1111/j.1365-2125.2012.04342.x
22. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC, for the MERIT-HF Study Group. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. *Eur Heart J* 2004;25:1300–09.
23. Dickstein K, Cohen-Solal A, Filippatos G. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J* 2008;29:2388–2442.
24. Doulas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, Tsiodras S, Dimitriou D, Giamarellou H. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared to normotensive individuals. *J Androl* 2006;27:469–77.
25. Dupont AG. Carvedilol and the kidney. *Clin Investig* 1992;70(Suppl 1):127–31.
26. Edelman JM, Lyle PA, Ang ZhZ. Letter to the editor. *Ann Intern Med* 2004;140:29.
27. Elliott W., Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: network meta-analysis. *Lancet* 2007;369:201–7.
28. Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. *Diabetologia* 1994;37:604–9.
29. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. *Eur J Heart Fail* 2001;3:469–79.

30. Erdmann E. Safety and tolerability of beta-blockers: prejudices ad reality. *Eur Heart J* – 2009;11(Suppl.A):21–5.
31. ESC Guildelines for the diagnosis and treatment of acute and chronic heart failure 2008. *Eur Heart J of Heart Failure* 2008;29:933–89.
32. Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, Gori T, Munzel T. β -Blockers in Patients With Intermittent Claudication and Arterial Hypertension Results From the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial. *Hypertension* 2011;58:148–54.
33. Evdokimov V, Radzevich A, Evdokimova A, Kovalenko E. Study of clinical efficacy of nebivolol and carvedilol administration in complex therapy of chronic heart failure due to coronary heart disease combined with chronic obstructive pulmonary disease. *Eur J Heart Failure Suppl* 2010;9:S20.
34. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentrerandomised study. *Int J ClinPract* 1999;53:519–22.
35. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, Galal W, Vidakovic RV, Tangelder MJ, Poldermans D. Cardioprotective medications associated with improved survive in patients with peripheral arterial disease. *J Amer Coll Cardiology* 2006;47(6):1182–87.
36. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215–25.
37. Fogari R., Preti P., Derosa G. Marasi G, Zoppi A, Rinaldi A, Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. *Eur J Clin Pharmacol* 2002;58:177–80.
38. Giuliano FA, Leriche A, Jaudinot E, Solesse de Gendre A. Prevalence of erectile dysfunction among 7689 patients with diabetes, hypertension, or both. *Urology* 2004;64:1196–1201.
39. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med* 1998;339:489–497.
40. Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, Yunis C, Svendsen K, Liebson PR, Elmer PJ. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS). *Hypertension* 1997;29:8–14.
41. Guan YY, Ye BH, Lu HH, Sheng ZQ, Zhang L, Hua SM, Tao GH, Yang QC. Study of carvedilol on plaque stability in carotid atherosclerotic rabbits transfected by p53 gene. *ZhonghuaXinXue Guan Bing ZaZhi* 2007;Vol.35:63–68. (Chinese).
42. Gundersen T, Kjekshus JK. Timolol treatment after myocardial infarction in diabetic patients. *Diabetes Care* 1983;6:285–290.

43. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000;356:359–365.
44. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity in hypertension: the Captopril Preventional Project (CAPP) randomised trial. *Lancet* 1999;353:611–616.
45. Hauf-Zachariou U, Widmann L, Zilsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. *Eur J Clin Pharmacol* 1993;45:95–100.
46. Hawkins N, MacDonald M, Petrie M, Chalmers GW, Carter R, Dunn FG, McMurray JJV. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. *European Journal of Heart Failure* 2009;11:684–690.
47. Hjalmarson A, Elmekdt D, Herlitz J, Holmberg S, Malek I, Nyberg G. Effect on mortality of metoprolol in acute myocardial infarction, a double-blind randomised trial. *Lancet* 1981;2(8251):823–7.
48. <http://www.ehealthme.com/ds/carvedilol/erectile+dysfunction>.
49. <http://www.reuters.com/article/2011/05/31/us-beta-blockers-idUSTRE74U6OD20110531>.
50. http://www.theheart.org/article/1453397.do?utm_medium=email&utm_source=20121003_EN_Heartwire&utm_campaign=newsletter.
51. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. *Am Heart J* 2003;146:848–853.
52. ISIS-1 (First International Study on Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. *Lancet* 1986;2(8498):57–66.
53. Ito H, Nagatomo Y, Kohno T, Anzai T, Meguro T, Ogawa S, Yoshikawa T. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. *Circ J* 2010;74:1578–1583.
54. Jaffe A, Chen Y, Kisch ES, Beno Fischel, Malbina Alon, Naftali Stern. Erectile dysfunction in hypertensive subjects: assessment of potential determinants. *Hypertension* 1996;28:859–862.
55. Kalaitzidis R, Bakris G. Should nephrologists use beta-blockers? A perspective. *Nephrol Dial Transplant* 2009;24:701–702.
56. Kjekshus J, Glipin E, Cali G, Blackey, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. *Eur Heart J* 1990;11:43–50.

57. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *The American Journal of Medicine* 2003;115:41–46.
58. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. *JAMA* 2002;288:351–357.
59. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. *Eur Heart J* 2003;24:464–474.
60. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. *Am J Cardiol* 2005;95:29–35.
61. Krause T., Lovibond K., Caulfield M, McCormack T, Williams B, on behalf of the Guideline Development Group. Management of hypertension: summary of NICE guidelines. *BMJ* 2011;343:4891.
62. Krum H, Hill J, Fruhwald F, Sharpe C, Abraham G, Zhu JR, Poy C, Kragten JA. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. *Eur J Heart Fail* 2006;8:302–307.
63. Kuller LH, Ockene JK, Townsend M, Browner W, Meilahn E, Wentworth DN. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. *Am Rev Respir Dis* 1989;140:76–81.
64. Kveiborg B, Hermann T., Atheline Major-Pedersen A, Christiansen B, Rask-Madsen Ch, Raunsø J, Køber L, Torp-Pedersen Ch and Dominguez H. Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes – a randomized study. *Cardiovascular Diabetology* 2010;9:21–30.
65. Law M, Morris J K, Wald N J. Use of blood pressure lowering drugs in the p context of expectations from prospective revention of cardiovascular disease: meta-analysis of 147 randomised trials in the epidemiological studies. *BMJ* 2009;338:1665.
66. Leinck JR. In introduction to cardiovascular physiology. London: Butterworth,1991.279 p.
67. Leonetti G, Egan C. Use of carvedilol in hypertension: an update. *Vascular Health and Risk Management* 2012;8:307–322.
68. Lever A, Brennan P. MRC trial of treatment in elderly hypertensives. *High Blood Press* 1992;1:132–137.
69. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005;366:1545–1553.
70. Malmberg K, Herlitz J, HjalmarsonE, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. *Eur Heart J* 1989;10:423–428.

71. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertension* 2009;27:2121–58.
72. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. *Adv Ther* 1995;12:212–221.
73. Marfella R, Siniscalchi M, Nappo F, Gualdiero P, Esposito K, Sasso FC, Cacciapuoti F, Di Filippo C, Rossi F, D'Amico M, Giugliano D. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. *Am J Hypertens* 2005;18:308–331.
74. Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients. *Hypertension* 2009;54:716–723.
75. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Piña IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. *Eur J Heart Fail* 2005;7:710–721.
76. Menghini F. The role of beta-blocker therapy in the treatment of arterial hypertension. First International Symposium Hypertension 1996: One Medicine, Two Cultures.
77. Messerli FH, Macdonald G, Brown MJ, Poole-Wilson PA, Horton R. Are calcium antagonists safe? *Lancet* 1995;346:767–769.
78. Messerli F, Bangalore S, Julius S. Risk/Benefit assessment of beta-blockers and diuretics precludes their use for first line therapy in hypertension. *Circulation* 2008;117:2706–2715.
79. Messerli F, Grossman E. Beta-blocker therapy and depression. *JAMA* 2002;288:1845–1846.
80. Messerli F, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the Elderly? *JAMA* 1998;279:1903–1907.
81. Messerli FH, Beevers DG, Franklin SS, Pickering TG. beta-Blockers in hypertension – the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. *Am J Hypertens* 2003;16:870–873.
82. Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. *Diabetes* 1990;39:76–82.
83. Nakamura M, Sato K, Nagano M. Estimation of aortic systolic blood pressure in community-based screening: the relationship between clinical characteristics and peripheral to central blood pressure differences. *J. Hum. Hypertens* 2005;19:251–253.

84. National Kidney Foundation. Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Executive summary. New York: K/DOQI Learning System (KLS)TM,2002.94 p.
85. Neal B, MacMahon S, Chapman N. Effects of AcE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. **Blood Pressure Lowering Treatment Trialists' collaboration.** *Lancet* 2000;356:1955.
86. Neglia D, De Maria R, Masi S, Gallopin M, Pisani P, Pardini S, Gavazzi A, L'Abbate A, Parodi O. Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. *Heart* 2007;93:808–813.
87. Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P, Johnson JA, Epstein BJ. Carvedilol Reduces Aortic Wave Reflection and Improves Left Ventricular/Vascular Coupling: A Comparison With Atenolol (CENTRAL Study). *The Journal of Clinical Hypertension* 2011;13:917–924.
88. Nur-Mammadova G, Mustafayev I. State of autonomic nervous system, penile hemodynamic and sexual function in men with arterial hypertension. Abstract. *J Hypertens* 2010;28:475e.
89. Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, Dige-Petersen H, Ibsen H. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. *Blood Press* 2005;14:177–183.
90. Ong H. Beta-blockers in hypertension and cardiovascular disease. *BMJ* 2007;334:946–949.
91. Ong K, Delorme S, Pannier B et al. on behalf of the investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. *Journal of Hypertension* 2011;29:1034–1042.
92. Opie LH, Gershbj J (eds). *Drugs for the Heart*, 7th edn. Philadelphia: Elsevier,2008.
93. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. *Eur J Vasc Endovasc Surg* 2009;38:66–70.
94. Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. *Curr Opin Nephrol Hypertens* 1994;3:292–300.
95. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven L, Scheffer MG, Trocino G, Vigna C, Baars HF, van Urk H, Roelandt JRTC. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. Bisoprolol reduces cardiac death and myocardial infarction in high risk patients as long as 2 years after successful major vascular surgery. *Eur Heart J* 2001;22:353–1358.
96. Poldermans D, Boersma E, Bax JJ, Thomson I, van de Ven L, Blankensteijn J, Baars HF, Tik-Ien Yo, Trocino G, Vigna C, Roelandt J, Fioretti PM, Paelinck B, van Urk H, for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. *N Engl J Med* 1999;341:1789–1794.

97. Polynia J, Barbosa L, Silva J, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with [beta]-blockers either with or without vasodilator properties or with angiotensin receptor blockers. *Blood Pressure Monitoring* 2010;15:235–239.
98. Poole-Wilson PA, Swedberg K, Cleland JGF, for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003;362:7–13.
99. Prisant LM, Weir MR, Frishman WH, Neutel JM, Davidov ME, Lewin AJ. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide. *J ClinHypertens*1999;1:22–26.
100. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med* 1991;151:1769–1776.
101. Ryden L, Standl E, Bartnik M. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary: the Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes. *Eur. Heart J* 2007;28:88–136.
102. Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. *J Am CollCardiol* 2009;54:1730–1734.
103. Rudberg S, IIIsterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1999;42:589–595.
104. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. *Ann Intern Med* 2002;137:715–725.
105. Sawicki PT, for the Diabetes Teaching and Treatment Programmes Working Group. Stabilisation of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. *Nephrol Dial Transplant* 1997;12:1890–1909.
106. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. *JAMA* 1996; 275:1507–13.
107. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain. A systematic analysis. *Hypertension* 2001;37(2):250–254.
108. Sharman JE, Stowasser M, Fassett RG, Marwick TH, Franklin SS. Central blood pressure measurement may improve risk stratification. *J. Hum. Hypertens* 2008;22:838–844.
109. Shiri R, Koskimäki J, Häkkinen J, Auvinen A, Tammela TL, Hakama M. Cardiovascular Drug Use and the Incidence of Erectile Dysfunction. *Int. J. Impot. Res* 2007;19(2):208–212.

110. Short P, Lipworth S, Elder D, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. *BMJ* 2011;342:d2549.
111. Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, Rosano G. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. *Eur Heart J* 2003;24:1928–1932.
112. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. *Proc Am Thorac Soc* 2005;2:8–11.
113. Staeson JA, Wang JG, Thigs L. Cardiovascular prevention and blood pressure reduction. *J Hypertens* 2003;21:1055.
114. Sugioka K, Hozumi T, Takemoto Y, Ujino K, Matsumura Y, Watanabe H, Fujimoto K, Yoshiyama M, Yoshikawa J. Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: A serial transthoracic Doppler echocardiographic study FREE. *J Am Coll Cardiol* 2005;45:318–319.
115. Sugioka K, Hozumi T, Takemoto Y, Ehara S, Ogawa K, Iwata S, Oe H, Matsumura Y, Otsuka R, Yoshiyama M, Yoshikawa J. Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy. *Am Heart J* 2007;153:1080.
116. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. *N Engl J Med* 1985;6:199–226.
117. Toblli JE, Stella I, Inserra F, Ferder L, Zeller F, Mazza ON. Morphological changes in cavernous tissue in spontaneously hypertensive rats. *Am J Hypertens* 2000;13:686–692.
118. Toblli J, Stella I, Néstor Mazza O, Ferder L, Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats: beyond blood pressure control. *Am J Hypertens* 2004;17:516–522.
119. Tomita K, Marumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. *J Cardiovasc Pharmacol* 1992;19(Suppl 1):97–101.
120. Ushiyama M, Morita T, Kuramochi T, Yagi S, Katayama S. Erectile dysfunction in hypertensive rats results from impairment of the relaxation evoked by neurogenic carbon monoxide and nitric oxide. *Hypertens Res* 2004;27:253–261.
121. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. *Hypertension* 2004;43:963–969.
122. Verza M, Ammendola S, Cambardella A, Scoti G, Vescio S, Tortoriello R, Amato L, Cerqua G, Varricchio G. Regression of left ventricular hypertrophy in hypertensive elderly patients with carvedilol. *Arch Gerontol Geriatr* 1996;22(Suppl 1):143–147.
123. Viigimaa M, Doumas M, Vlachopoulos C, Anyfanti P, Wolf J, Narkiewicz K, Mancia G. Hypertension and sexual dysfunction: time to act. *J Hypertens* 2011;29:403–407.

124. Vilkmann S, Keistinen T, Tuuponen T, Kivela SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. *Respiration* 1997;64:281–284.
125. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M. Carotid Intima-Media Thickness and Antihypertensive Treatment A Meta-Analysis of Randomized Controlled Trials. *Stroke* 2006;37:1933–1940.
126. Weidmann P, Boehlen M, de Courten M. Effects of different antihypertensive drugs on human proteinuria. *Nephrol Dial Transplant* 1993;8:582–584.
127. Wendt T. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. *J Molecular Medicine* 1992;Suppl.2:93–97.
128. Wilkinson IB, Franklin SS, Hall IR, Tyrrell S, Cockcroft JR. Pressure Amplification Explains Why Pulse Pressure is unrelated to risk in young subjects. *Hypertens* 2001;38:1461–1466.
129. Williams B. b-blockers and the treatment of hypertension. *Journal of Hypertension* 2007;25:1351–1353.
130. Williams B, Lacy P. for the CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators Impact of Heart Rate on Central Aortic Pressures and Hemodynamics Analysis From the CAFE (Conduit Artery Function Evaluation) Study: CAFE-Heart Rate. *J. Am. Coll. Cardiol* 2009;54:705–713.
131. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006;113:1213–1225.
132. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension (Review). John Wiley & Sons, Ltd: 2012.77 p.
133. Wu TC, Chen YH, Leu HB. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. *Free Radic Biol Med* 2007;43:1508–1522.
134. Yue TL, Lysko PG, Barone Fc. Carvedilol, a new antihypertensive with unique antioxidant activity: potential role of cerebroprotection. *Ann N Y Acad Sci* 1994;738:230–242.
135. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. *Circulation* 2002;106:2422-2427.